# Neoadjuvant Docetaxel in Treating Women With Newly Diagnosed Breast Cancer

> **NCT00080626** · PHASE2 · TERMINATED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 19 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** pegfilgrastim
- **DRUG:** docetaxel
- **PROCEDURE:** conventional surgery
- **PROCEDURE:** neoadjuvant therapy

## Key facts

- **NCT ID:** NCT00080626
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-08-11
- **Primary completion:** 2006-05-01
- **Final completion:** 2006-05-01
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** low accrual
- **Last updated:** 2019-03-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00080626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00080626, "Neoadjuvant Docetaxel in Treating Women With Newly Diagnosed Breast Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00080626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*